EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
Evogene Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$0.37−0.02 (-4.71%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.3
- Dividend yield
- –
Share price
−$0.8820 (−70.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Evogene Ltd. saw revenue fall 30.9% to $3.85M over fiscal 2025. Free cash flow was -$13.64M.
Revenue
$3.85M
-30.9% vs. a year earlier
Operating income
-$14.03M
FY2025
Free cash flow
-$13.64M
FY2025
EPS, diluted
$1.08
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- 0.3
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.85M
- Net income
- -$8.49M
- EPS, diluted
- $1.08
- Free cash flow
- -$13.64M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$3.85M-30.9% YoY
Gross profit
-$241.00K-107.5% YoY
Operating income
-$14.03M
Net income
-$8.49M
EPS, diluted
$1.08
Free cash flow
-$13.64M
Reported period